Statement of Principles concerning dermatomyositis (Balance of Probabilities) (No. 71 of 2022)

The central legal concept is evidentiary determinism within the statutory SoP framework: the Repatriation Medical Authority identifies, from its view of the medical‑scientific evidence, which factual factors can, when related to a person’s relevant service, support a finding that dermatomyositis or death from dermatomyositis is service‑related on the balance of probabilities (s 8 and s 9). The SoP sets out three linked concepts that decision-makers must apply.

First, definitional scope. Dermatomyositis is defined in s 7(2) as a chronic inflammatory disease with inflammatory skin changes usually accompanied by progressive and symmetric skeletal muscle weakness, and it expressly includes amyopathic dermatomyositis. The Schedule reiterates that dermatomyositis is as per s 7(2). The instrument’s notes (s 7(2) notes) identify typical clinical features and confirmatory investigations that are relevant to diagnosis: heliotrope rash, Gottron papules, serum muscle-associated enzyme elevation, biopsy, imaging or myositis-associated antibodies, and the amyopathic variant description. Death from dermatomyositis is included where death was contributed to by the person’s dermatomyositis, and the Schedule defines “terminal event” with examples such as pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (s 7(3); Schedule 1).

Second, the enumerated factors. Section 9 lists the alternate factors, any one of which must exist before a decision-maker may conclude the disease or death is connected with service. They are structured to address both initial clinical onset and later clinical worsening. For onset the instrument includes: taking a drug from the specified list for at least 4 weeks prior to clinical onset (s 9(1)); taking hydroxyurea for at least 6 months prior to onset (s 9(2)); taking an immune checkpoint inhibitor or interferon alfa within one year prior to onset (s 9(3)); taking a drug in the individual associated with onset where the drug was used for at least 7 days and there is improvement within two months of stopping or symptom recurrence on rechallenge (s 9(4)); and having a malignant neoplasm other than non‑melanotic malignant neoplasm of the skin within 5 years of clinical onset (s 9(5)). Parallel provisions address clinical worsening (s 9(6)-(10)), and an additional factor for worsening or onset includes inability to obtain appropriate clinical management for dermatomyositis (s 9(11)).

Third, the relationship-to-service rule. Any factor the claimant relies on must be “related to the relevant service rendered” by the person (s 10(1)). Further, subsections 9(6) to 9(11) apply only where the dermatomyositis was suffered or contracted before or during, but did not arise out of, the person’s relevant service; in that circumstance those factors operate only to establish material contribution to or aggravation of the pre‑existing condition (s 10(2)). The Schedule precisely delimits “relevant service” to eligible war service (other than operational service) under the VEA, defence service (other than hazardous service and British nuclear test defence service) under the VEA, or peacetime service under the MRCA.

The instrument also includes a cross‑reference mechanism: if a factor refers to an injury or disease that itself is the subject of a separate SoP under s 196B(3) of the VEA, then the factors in that other SoP apply according to their terms (s 11). The specified list of drugs is given in the Schedule (5‑fluorouracil; capecitabine; D‑penicillamine; statins; tumour necrosis factor-alpha inhibitors), and examples of immune checkpoint inhibitors are noted in the main text (s 9 notes).

This SoP affects three stakeholder groups identified by the instrument: claimants (veterans and members of the Forces), decision-makers applying the VEA and MRCA provisions identified in s 5, and treating clinicians whose records will supply the evidence claimants need.

Claimants: The instrument “applies to a claim to which section 120B of the VEA or section 339 of the MRCA applies” (s 5). The Schedule defines “relevant service” narrowly. Under the Schedule relevant service means eligible war service (other than operational service) under the VEA; defence service (other than hazardous service and British nuclear test defence service) under the VEA; or peacetime service under the MRCA. The exclusions in the Schedule are consequential: operational service, hazardous service and British nuclear test defence service are not part of the defined relevant service categories for this SoP. Consequently, claimants must both satisfy the medical factors in s 9 and have the factor related to one of the specified types of relevant service per s 10(1).

Decision-makers: The Repatriation Medical Authority has made the SoP under its statutory power (s 3). The SoP functions as the Authority’s view of the medical‑scientific evidence that supports a connection on the balance of probabilities (s 8). Decision-makers exercising powers under the VEA or MRCA that incorporate or require application of SoPs will use this instrument to determine whether dermatomyositis or death from dermatomyositis is service-related. The instrument requires them to check that at least one of the listed factors exists (s 9), and to apply the relationship-to-service rules in s 10. Where a listed factor refers to an injury or disease that is subject to another SoP, the decision-maker must apply that other SoP’s factors as they are in force from time to time (s 11).

Clinicians and records custodians: The SoP’s notes in s 7(2) list forms of clinical confirmation that are relevant to diagnosis , serum levels of muscle-associated enzymes, biopsy, imaging, myositis-associated antibodies , and the Schedule identifies the precise drugs and terminal events. This means clinicians’ records on diagnosis, medication history with start and stop dates, outcomes after drug cessation, rechallenge records, cancer diagnoses with dates, and documentation about access to or inability to obtain clinical management are the primary evidentiary sources claimants will need to rely on. The instrument therefore affects clinicians indirectly, by setting the types and temporal detail of records that will be material to decision-makers.

No penal or criminal sanctions are created by the instrument itself. Its operational effect is evidentiary: it governs how claims for compensation or entitlements are to be assessed against the SoP’s listed factors and the relationship-to-service requirements (s 5, s 8-s 11).

The instrument creates procedural and evidential obligations for decision-makers and practical rights for claimants through the specified factors and relationship requirements. The SoP itself does not create statutory duties in the sense of offences or regulatory obligations. Rather, it establishes what must be shown, on the balance of probabilities, for a finding of service connection.

Duty to apply the SoP: The Repatriation Medical Authority has issued the SoP under s 196B(3) of the VEA (s 3). Decision-makers charged with applying the VEA and MRCA provisions cited in s 5 must treat the SoP as the Authority’s expression of the medical evidence that supports linking dermatomyositis to relevant service. Practically, that imposes an obligation on decision-makers to examine whether at least one of the factors in s 9 is present and related to the person’s relevant service (s 9; s 10(1)). The SoP also requires decision-makers to apply the linkage rules in s 10(2) for factors pertaining to worsening when the condition pre-existed service.

Requirement to find a factor: The SoP states that “At least one of the following factors must exist before it can be said that, on the balance of probabilities, dermatomyositis or death from dermatomyositis is connected with the circumstances of a person's relevant service” (s 9). That is the principal evidentiary threshold: a decision-maker needs to be satisfied a listed factor exists, then satisfied that that factor is related to relevant service.

Right to rely on clinical diagnostic standards listed: The notes under s 7(2) specify diagnostic evidence that may confirm dermatomyositis, such as elevated serum muscle-associated enzymes, biopsy, imaging, or myositis-associated antibodies. Clinicians’ objective findings and results therefore operate as material evidence that supports a claimant’s right to have their condition assessed under the SoP.

Temporal and causal requirements: The SoP imposes explicit temporal thresholds for certain drug exposures before clinical onset or worsening. For example, the specified list of drugs must have been taken for at least 4 weeks before clinical onset (s 9(1)); hydroxyurea for at least 6 months before onset (s 9(2)); immune checkpoint inhibitors or interferon alfa within one year before onset (s 9(3)). For drug-associated onset or worsening where improvement after cessation or rechallenge is alleged, the drug must have been taken for at least 7 days before the event, and improvement must occur within two months of discontinuing or tapering the drug for the factor in s 9(4) and s 9(9) to apply.

Cross‑SoP interaction duty: Where a factor in s 9 refers to another injury or disease that has its own SoP, the decision‑maker must apply the factors in that other SoP “in accordance with the terms of that Statement of Principles as in force from time to time” (s 11). This creates a duty to consult and apply the current terms of the other SoP(s) referenced.

Right to have aggravation considered: If dermatomyositis was suffered or contracted before or during relevant service but did not arise out of the service, subsections 9(6) to 9(11) can only be used to establish material contribution to, or aggravation of, the condition (s 10(2)). This is a right claimants can assert where pre-existing disease is alleged to have been aggravated by service-related factors.

No offence regime in the instrument: The SoP does not create fines, criminal penalties or compliance regimes. Its rights and duties are evidentiary and administrative: showing a factor and the relationship to relevant service enables entitlement findings under the VEA or MRCA frameworks that incorporate or rely on SoPs (s 5; s 8).

The instrument contains no provisions that create criminal offences, civil penalties or direct enforcement powers. It is an evidentiary instrument issued under s 196B(3) of the VEA (s 3). Its operative effect is to inform administrative decision-making about service connection for dermatomyositis and death from dermatomyositis; it does not itself impose sanctions for non‑compliance or set out enforcement mechanisms.

How it is enforced in practice is by administrative application within the VEA and MRCA claims processes. Section 5 prescribes the SoP’s application to claims made under s 120B of the VEA or s 339 of the MRCA. Those statutes and their administrative frameworks govern the processing, determination and possible reviews or appeals of claims. This SoP functions as the Repatriation Medical Authority’s statement of the medical‑scientific factors decision-makers should rely upon when determining whether dermatomyositis is related to relevant service. The instrument therefore affects the merits of entitlement determinations rather than establishing penalty regimes.

There is a practical enforcement dynamic for decision-makers: if a decision-maker departs from the Authority’s SoP view when adjudicating under the VEA or MRCA, that departure may be relevant in subsequent merits review or judicial review processes. However, the instrument itself contains no procedural enforcement instructions, remedies or penalty provisions; those reside in the VEA, MRCA and associated administrative law mechanisms outside the text of this SoP.

The Schedule defines terminal events and specified drugs and thereby circumscribes the factual bases that a decision-maker will use when assessing causation in death or medicine-related onset or worsening. The instrument’s examples and definitions reduce uncertainty about what evidence is materially relevant, but enforcement of assessments remains within the statutory claims framework. The instrument’s repeal of the prior SoP (s 4) means that decision-makers must apply the current SoP from its commencement date (s 2) in relation to claims to which it applies, but the instrument does not itself prescribe transitional penalty or enforcement arrangements.

This SoP is made under s 196B(3) of the VEA (s 3) and explicitly applies to claims under s 120B of the VEA and s 339 of the MRCA (s 5). It therefore interacts with the substantive and procedural provisions of the VEA and MRCA as those Acts govern entitlement determination, appeals and any review processes. The instrument itself does not amend the VEA or MRCA; it operates within the statutory SoP mechanism established by s 196B(3) of the VEA.

Cross‑SoP interaction: Section 11 creates an explicit interaction mechanism with other Statements of Principles made under s 196B(3) of the VEA. If a factor in s 9 refers to an injury or disease that is the subject of another SoP, then the factors in that other SoP “apply in accordance with the terms of that Statement of Principles as in force from time to time.” This requires decision-makers to treat cross-referenced SoPs as incorporated by reference where applicable and to apply those other SoP factors according to their current terms, including any amendments. It creates an obligation to consult the up‑to‑date text of other SoPs where a s 9 factor depends on them.

Repeal of previous SoP: The instrument repeals the Statement of Principles concerning dermatomyositis No. 10 of 2014 (s 4). That repeal brings the current SoP into legal effect from its commencement on 25 July 2022 (s 2) and removes the earlier instrument from the set of applicable SoPs. Decision-makers must therefore apply the No. 71 of 2022 SoP for claims to which this instrument applies; the instrument does not itself state transitional arrangements for claims lodged before commencement, beyond the general application provision in s 5.

Interaction with diagnostic and clinical standards: The instrument’s notes in s 7(2) reference diagnostic aids , serum enzyme elevation, biopsy, imaging, myositis-associated antibodies , as confirmatory evidence of dermatomyositis. This interacts functionally with clinical records and diagnostic practice. Decision-makers will rely on medical records showing these diagnostic findings in assessing whether dermatomyositis exists for claims purposes.

Interaction with drug and malignant disease-specific law: The Schedule lists particular drugs and drug classes (5‑fluorouracil; capecitabine; D‑penicillamine; statins; tumour necrosis factor-alpha inhibitors) and the main text names immune checkpoint inhibitors and interferon alfa as implicated classes (s 9 and Schedule). When a s 9 factor refers to another disease or injury that itself has its own SoP, the SoP framework requires the decision-maker to integrate the other SoP. This can create multi-instrument interaction where causation or contribution traverses multiple conditions and their respective SoPs.

No express interaction with other statutory regimes such as workers’ compensation or civil liability statutes appears in the text. The SoP is an administrative evidentiary instrument operating within the VEA/MRCA statutory scheme; any cross-claims under other statutory or common law regimes are outside its scope as stated in the instrument.

This instrument is the Statement of Principles concerning dermatomyositis (Balance of Probabilities) (No. 71 of 2022). The front matter records the instrument was dated 24 June 2022 and commenced on 25 July 2022 (s 2). It was made under subsection 196B(3) of the Veterans' Entitlements Act 1986 (s 3). Section 4 expressly repeals the earlier Statement of Principles concerning dermatomyositis No. 10 of 2014 (Federal Register of Legislation No. F2014L00011), which had been made under the same statutory power.

The Schedule and main text contain the operative substantive changes relative to the prior SoP, as reflected by the repeal provision. The instrument identifies itself as No. 71 of 2022; the numbering and dating place it in the sequence of SoPs issued by the Repatriation Medical Authority. The instrument includes a note of the Common Seal and names the Chairperson, Professor Terence Campbell AM, indicating formal execution.

No other amendments, repeal savings, or transitional provisions are provided in the instrument text itself. The instrument does not specify retrospective application mechanics, nor does it include express savings clauses for decisions made under the prior SoP. The practical implication is that from its commencement date decision-makers should apply this SoP for claims to which s 120B of the VEA or s 339 of the MRCA apply. The instrument does not record any subsequent amendments within the text provided.

Because this instrument repealed the 2014 SoP, any differences between the two SoPs would govern current determinations; the instrument text must be read alongside the VEA and MRCA statutory processes for appeals and reviews to determine how determinations made under the 2014 SoP are treated administratively. The instrument itself does not specify whether decisions made before commencement are to be revisited or how pending claims at the time of repeal are to be handled, beyond the general operation under s 5 that it applies to claims to which the named VEA and MRCA sections apply.

The instrument contains no litigation history, references to cases, or examples of judicial consideration. The text does not name any legal proceedings, courts, tribunals, merits review decisions or precedent authorities. It is a Statement of Principles made by the Repatriation Medical Authority under the VEA and therefore functions as an administrative evidentiary standard for decision-makers assessing claims under s 120B of the VEA and s 339 of the MRCA (s 5).

Because no cases are cited in the instrument, there is no litigation record contained in the text to support or challenge its factors. The instrument’s own note in s 8 asserts the Authority’s view about the medical‑scientific evidence , that it is more probable than not that dermatomyositis and death from dermatomyositis can be related to relevant service , but it does not summarise the studies, reports or adjudicative decisions that underpinned that view. The instrument therefore provides the Authority’s determinations of applicable factors without an accompanying catalogue of empirical or adjudicative footnotes in the instrument text.

Practitioners seeking litigation history relevant to this SoP will need to consult administrative decisions, tribunal determinations and court judgments arising from VEA or MRCA claims that reference dermatomyositis or this SoP. None of that material is in the instrument itself.

The instrument contains several drafting and evidential points that create potential pitfalls for claimants, advisers and decision‑makers. These are matters of precise text, timing and cross‑instrument application rather than policy evaluations.

1. Temporal thresholds are precise and differ by drug category. The SoP imposes minimum exposure durations and look‑back periods for specified drug exposures before clinical onset or worsening. For clinical onset, a drug from the specified list must have been taken for at least 4 weeks before onset (s 9(1)); hydroxyurea must have been taken for at least 6 months before onset (s 9(2)); immune checkpoint inhibitors or interferon alfa must have been taken within one year before onset (s 9(3)). For drug-associated onset/worsening where cessation or rechallenge evidence is relied upon, the drug must have been taken for at least 7 days before the relevant clinical event and improvement must occur within 2 months of discontinuing or tapering (s 9(4) and s 9(9)). Failure to document exact start and stop dates, or to show that these thresholds were met, can defeat reliance on the corresponding factor.

2. “Taking a drug” and evidence burdens. The SoP uses the expression “taking a drug” but does not define pharmacological exposure in pharmacokinetic or dosing terms. Decision-makers will therefore require documentary proof that the individual was prescribed, dispensed and actually took the drug for the requisite period. Prescription records, dispensing history, clinician notes about adherence, and hospital medication charts will be the critical items of evidence. Absent clear records, the claimant may fail to meet the s 9 threshold.

3. The 7‑day minimum for drug-associated causation and the 2‑month improvement window can be narrow. For factors relying on improvement after discontinuation or redevelopment on rechallenge (s 9(4) and s 9(9)), the SoP requires that the drug was taken for at least 7 days prior to onset/worsening and that improvement occurs within two months of stopping or tapering. Clinical courses that do not fit within these windows may not satisfy the factor even where the clinician suspects a drug cause. Rechallenge evidence is not commonly available; absence of rechallenge or clear improvement within two months will weaken reliance on these factors.

4. The “inability to obtain appropriate clinical management” factor is conceptually broad and not defined. Section 9(11) lists inability to obtain appropriate clinical management as a factor without specifying what constitutes “appropriate,” who determines adequacy, or thresholds for attempting or seeking treatment. Decision-makers will face uncertainty about the standard of proof and the nature of evidence required. Documentary evidence of referral attempts, waitlists, geographical or service access constraints and clinician opinions about deprivation of care will be relevant, but the SoP leaves the precise test to administrative application.

5. Relationship-to-service timing constraints for aggravation. Subsections 9(6) to 9(11) apply only to material contribution to, or aggravation of, dermatomyositis where the person’s dermatomyositis was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s 10(2)). That means if dermatomyositis first arose out of service, these particular factors for worsening may not be applicable in the same manner. Practitioners must carefully map the chronology of disease onset relative to relevant service to identify which s 9 subparagraphs are available.

6. “Relevant service” exclusions. The Schedule’s definition of relevant service excludes operational service within eligible war service, hazardous service and British nuclear test defence service under the VEA. If the claimant’s service falls within one of those excluded categories, the SoP will not apply as drafted. This may be counter‑intuitive to practitioners who assume military service generally qualifies a claimant for the SoP’s benefit.

7. Cross-references to other SoPs can complicate proof. Section 11 requires the application of another SoP’s factors where a s 9 factor refers to an injury or disease that already has its own SoP. This can add layers of evidentiary complexity where drug exposure or malignancy interacts with other conditions that have distinct SoP requirements. Practitioners must identify and compile evidence relevant to each cross-referenced SoP.

8. Diagnostic ambiguity and the amyopathic variant. The instrument expressly includes amyopathic dermatomyositis in the definition (s 7(2)(b) and the note to s 7(2)). Amyopathic cases may lack objective muscle weakness, relying instead on skin findings and other tests for diagnosis. Decision-makers will require clear documentation of skin signs and any serological or imaging findings. The absence of muscle weakness does not preclude the condition, but it may require different forms of objective evidence which are less commonly standardised in clinical records.

9. Death causation requires linking terminal events to dermatomyositis. For death claims the Schedule defines terminal events broadly (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). The instrument requires that death be “from a terminal event or condition that was contributed to by the person's dermatomyositis” (s 7(3)). Establishing that a terminal event was contributed to by dermatomyositis will require medical records, cause-of-death certificates and clinician opinions linking the disease to the terminal event.

10. Repeal timing and application. The instrument repeals the 2014 SoP (s 4) and commenced on 25 July 2022 (s 2). The text does not provide transitional directions for claims lodged or decided under the prior SoP. Advisers should check administrative practice guidance and decision-maker directions for how claims that straddle repeal and commencement are handled, because the instrument itself is silent on transitional administrative mechanics.

For claimants and their advisers

1. Establish the diagnosis: Obtain and collate all objective diagnostic evidence consistent with s 7(2) notes: clinician notes describing classic skin signs (heliotrope rash, Gottron papules), serum muscle-associated enzyme results, muscle biopsy reports, imaging (for example MRI) showing muscle inflammation, and myositis-associated antibody testing. The SoP explicitly lists these items as confirmatory in the notes to s 7(2), and including them will make it more straightforward for decision-makers to accept that dermatomyositis exists for claims purposes.

2. Map clinical chronology to relevant service: Precisely document dates of relevant service and dates of clinical onset and any subsequent clinical worsening. Section 10(1) requires that any factor relied on must be related to the person’s relevant service. For subsections 9(6) to 9(11), ensure the record shows dermatomyositis was suffered or contracted before or during, but did not arise out of, the relevant service, if relying on those aggravation factors (s 10(2)).

3. Medication exposure proofs: For each drug mentioned in s 9, obtain prescribing records, dispensing records, hospital medication charts and clinician notes documenting start and stop dates and adherence. The Schedule lists the specified drugs (5‑fluorouracil; capecitabine; D‑penicillamine; statins; tumour necrosis factor-alpha inhibitors). For hydroxyurea rely on documentation of at least 6 months’ continuous use prior to onset (s 9(2)). For specified list drugs, show at least 4 weeks use prior to onset (s 9(1)). For checkpoint inhibitors or interferon alfa, document any administration within one year prior to onset (s 9(3)). For drug-associated causation points that require at least 7 days’ exposure and improvement within two months of cessation, provide contemporaneous clinician notes showing symptom trajectory pre- and post-cessation and any rechallenge records (s 9(4) and s 9(9)).

4. Malignancy linkage: If relying on s 9(5) or s 9(10), obtain oncology records and histopathology confirming the diagnosis and dates. The SoP requires a malignant neoplasm, other than non‑melanotic malignant neoplasm of the skin, within five years of clinical onset or clinical worsening. Ensure dates demonstrate the five year window is met.

5. Document attempts to obtain clinical management: If relying on s 9(11), assemble contemporaneous evidence of inability to obtain appropriate clinical management. This may include referral letters, waiting list notices, denial of care correspondence, expert clinician opinions on local service insufficiency, or other documentary evidence showing that the claimant sought but could not obtain appropriate management. The SoP does not define “appropriate clinical management”, so contemporaneous records that support the claimant’s narrative are essential.

6. Death claims: For deaths, assemble the full death certificate, hospital and coronial records where applicable, statements linking the terminal event to dermatomyositis, and clinician opinions as to contribution. The Schedule lists terminal events and the SoP requires death from a terminal event or condition that was contributed to by the person’s dermatomyositis (s 7(3); Schedule).

7. Prepare for cross‑SoP issues: Identify whether any factor in s 9 refers to another disease or injury that has its own SoP. If so, obtain evidence necessary to satisfy that other SoP, because s 11 requires the decision-maker to apply the other SoP’s factors as in force from time to time.

For decision‑makers and administrators

1. Apply the statutory thresholds strictly: The SoP sets minimum exposure and temporal thresholds. Verify documentary evidence meets the statutory thresholds in s 9 before accepting a factor. For example, confirm duration of hydroxyurea exposure of at least six months before onset for s 9(2) and a checkpoint inhibitor or interferon alfa exposure within one year for s 9(3).

2. Verify diagnosis using the forms of confirmation listed in s 7(2): Where diagnosis is in dispute, request or review objective testing, including enzyme levels, biopsy reports and imaging, and antibody testing noted in the SoP. For amyopathic dermatomyositis, recognise that absence of muscle weakness does not preclude the diagnosis if skin and other test evidence are present.

3. Require specific evidence for drug causation assertions: For factors involving drug cessation improvement or rechallenge (s 9(4) and s 9(9)), look for contemporaneous clinician observations or test results documenting improvement within two months after stopping or tapering the drug, or objective evidence of recurrence on rechallenge. Absent such evidence, the factor should not be accepted.

4. Evaluate the “inability to obtain appropriate clinical management” factor cautiously: Because s 9(11) is not defined in the instrument, decision-makers should seek detailed evidence about what management was sought, what was available, why it was not appropriate or accessible, and the causal link between lack of management and clinical onset or worsening. Obtain expert clinical input where necessary.

5. Respect cross‑SoP integration: Where s 9 refers to injuries or diseases that are themselves the subject of another SoP, apply those other SoP factors per s 11. Ensure up‑to‑date versions of other SoPs are consulted and applied.

6. Document relationship to relevant service: For any accepted factor, document the analysis explaining how the factor is related to the person’s relevant service as required by s 10(1). Where aggravation factors under s 9(6)-(11) are used, explain why the condition was suffered or contracted before or during but did not arise out of the relevant service, per s 10(2).

7. Note the repeal of the 2014 SoP: From 25 July 2022 decision-makers should apply this current SoP for claims under the cited VEA and MRCA sections (s 2, s 4, s 5). For cases that straddle the repeal, administrative guidance may be necessary; the SoP itself does not provide transitional rules.

8. Seek expert medical opinions where necessary: The SoP sets the factual gates; where medical causation is contested, decision-makers should obtain expert medical evidence specifically addressing the s 9 factors and the temporal and causal link to service.

9. Preserve appeal and review records: Because the SoP is evidence‑definitional within the VEA/MRCA claims environment, maintain clear records of the factual and medical reasoning for entitlement determinations, both for internal review and for merits or judicial review processes.

By following these steps claimants and decision-makers can align evidentiary collection and adjudication with the textually specified requirements of the SoP. The instrument sets discrete factual gates; compliance requires documentary proof of diagnosis, precise medication and exposure dates, clear timelines for cancer diagnosis when relevant, and recordation of attempts to obtain clinical management where that factor is asserted.